Skip to main content
OpenTrials
Completed

NCT Number: NCT03852238

Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver: Case-control Study (NoFlic Study)

The main objective of this study is to identify direct carcinogenic factors in the absence of cirrhosis, and the carcinogenesis pathways involved on nonfibrotic liver (NfCHC).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Amiens, Amiens, France

Loading trial locations.

About this study

Most hepatocellular carcinoma (HCC) complicates cirrhosis, which is often caused by infection with hepatitis B or C viruses, alcohol, obesity, exposure to aflatoxin B1 (AFB1) or hemochromatosis. Nevertheless, 10 to 40% of HCCs can develop on non-cirrhotic terrain and about 5% on nonfibrotic liver (NfHCC). In 20 to 40% of these NfHCCs, no classical HCC risk factor is identified. Some cases could be the result of a transformation of an adenoma. Others may be associated with yet non-formally identified toxins and / or a specific genetic predisposition. While there is a lot of data on alterations of signaling pathways (ß-catenin, AKT / mTOR, Ras / pERK, etc.) in "classical" HCCs, altered pathways remain unknown in most NfHCCs, even in some cases, activation of β-catenin, inactivating mutations of HNF1 or activators of gp130 have been shown. A specific study of NfHCCs, rather rare cancers, represents an opportunity to look for directly carcinogenic factors in the absence of cirrhosis, and to dissect the involved carcinogenesis pathways.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • CASES: patients aged 18 years and older with a diagnosis of NfHCC with anatomopathological examination and showing a HCC according to standard histopathological criteria and an absence of significant fibrosis in non-tumoral tissues with the METAVIR system score or equivalent (F0 or F1) or the Kleiner et al stage of ASH and NASH (≤stade 2); signed informed consent; affiliated or beneficiary of a social security system
  • CONTROLS: patients aged 18 years and older without NfHCC at baseline; patients for whom an endoscopy is programmed as part of an assessment of intestinal functional disorders, dyspeptic disorders or screening colonoscopy or hospitalized patients in orthopedic surgery / traumatology or rheumatology departments; signed informed consent; affiliated or beneficiary of a social security system

Exclusion criteria

  • CASES: HCC diagnosed without pathological examination; hepatic transplantation before the diagnosis of HCC; patients unable to answer questions; patients who do not speak French or live abroad.
  • CONTROLS: History of liver cancer; other cancers under treatment except cutaneous cancers; Colonoscopy indicated in case of familial form of colon cancer; patient with cirrhosis; patients unable to answer questions; patients who do not speak French or live abroad; Relationship or same home with the case

Treatment and study plan

Blood test and self-administrated questionnaires

Other

Primary outcomes

  1. exposure to Viral hepatitis B

    Time frame: Baseline

    binary yes / undiagnosed by positive serology for anti-HBc antibodies isolated or associated with positive serology for anti-HBs antibodies

Secondary outcomes

  1. exposure to viral hepatitis C

    Time frame: baseline

    binary yes / undiagnosed by positive serology for positive anti-HCV antibodies

Other outcomes

  1. exposure to Alcohol

    Time frame: baseline

    binary variable, separating large consumers from others

  2. exposure to Exogenous female hormones

    Time frame: baseline

    oral contraceptive coded as a binary variable

  3. history of liver pathology

    Time frame: baseline

    binary variable: yes/no

  4. Family history of liver cancer

    Time frame: baseline

    binary variable: yes/no

  5. Diabetes

    Time frame: baseline

    categorical variable (depending on the type of diabetes: 1 or 2).

  6. Dyslipidemias

    Time frame: baseline

    qualitative variables: hypercholesterolemia / hyper triglyceridemia

  7. Medical treatments for dyslipidemia

    Time frame: baseline

    depending on the type of medication: statins, fibrates, other

  8. Metabolic syndrome

    Time frame: baseline

    binary variable: present / absent

  9. Age of first menstruation

    Time frame: baseline

    quantitative variable in years

  10. Parity

    Time frame: baseline

    number of children

  11. breastfeeding

    Time frame: baseline

    binary variable : yes / no

  12. Menstrual status

    Time frame: baseline

    menopausal status will be treated as a binary variable

  13. Duration of exposure to different variables

    Time frame: baseline

    quantitative variable in months

  14. fruits

    Time frame: baseline

    frequency of intake assessed by a frequency food questionnaire

  15. vegetables

    Time frame: baseline

    frequency of intake assessed by a frequency food questionnaire

  16. meat

    Time frame: baseline

    frequency of intake assessed by a frequency food questionnaire

  17. fish

    Time frame: baseline

    frequency of intake assessed by a frequency food questionnaire

  18. dairy products

    Time frame: baseline

    frequency of intake assessed by a frequency food questionnaire

  19. fats

    Time frame: baseline

    frequency of intake assessed by a frequency food questionnaire

Sponsors and collaborators

Lead sponsor

University Hospital, Bordeaux

Other

Collaborators

  • National Cancer Institute, France

Registry information

Official study title

Risk Factors of Hepatocellular Carcinomas Developed on Non-fibrotic Liver (NoFlic Study)

Acronym: NoFlic

Important dates

Study start
2010
Primary completion
2013
Study completion
2013
First posted
Feb 25, 2019
Registry last updated
Feb 25, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.